BIO-FD&C CO.,LTD.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2005 and listed on KOSDAQ in 2022, BIO-FD&C develops and manufactures plant-cell-derived bioactive and pharmacological materials using its plant cell design and culture platform. Using SMART-RC2 mass-culture technology, it produces transgenic plant cell lines including recombinant growth factors, phytopeptides, and rose cell lines, and holds a pipeline of stem-cell stimulant P334-CT (Poripha334), incontinence treatment KSF-D (Kurarinone), and gastric cancer/gastritis treatment HelicoMab. It runs the Plant Cell Institute in Incheon (21 researchers) and the Pharmaceutical Nano Materials Institute in Gwangju-Jeonnam (13 researchers), holds about 250 plant cell lines with 120 cryopreserved, and supplies 25 mass-cultured cell lines to Givaudan, GINZATOMATO, SIYANLI, and BENEV.
Products & technology
- Plant cell lineMaterial for cosmeceuticals, health functional foods, and pharmaceuticals
- Recombinant growth factorCosmeceutical material
- PhytopeptideCosmeceutical material
- Rose cell lineTransgenic plant cell line material
- PDRN (Polydeoxyribonucleotide)Cosmetic material extraction technology
Regulatory approvals
data.go.kr3 Korean MFDS device approvals · 2024–2026
- MFDSDressing, fluid-impermeable film2026-04-06Product approval · Class 2제인 26-4303 호
- MFDSDressing, fluid-impermeable film2025-12-04Product approval · Class 2제인 25-5132 호
- MFDSDressing, fluid-impermeable film2024-10-17Product approval · Class 2제인 24-947 호
R&D and key agreements
Source: DART corporate disclosureP334-CT(포피라334) · 줄기세포촉진 · 시약 · Plant-cell-derived pharmacological material pipeline
KSF-D(쿠라리논) · 요실금치료 · 신약 · Plant-cell-derived pharmacological material pipeline
HelicoMab · 위암/위염치료 · 신약 · Plant-cell-derived pharmacological material pipeline
Companies approved for the same productsPharma & CDMO
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Daehan Pharmaceutical, founded in 1963 and KOSDAQ-listed in 1994, manufactures intravenous fluid pharmaceuticals.
KOSDAQ-listed comprehensive healthcare and pharmaceutical company behind the gum treatment Insadol and the wound-care ointment Madecassol.
Dongwha Pharm, founded in 1897 and KOSPI-listed in 1976, is a diversified company centered on pharmaceuticals.
KOSDAQ-listed medical device company producing human tissue implants Bella Cell HD and SureFuse.
KOSDAQ-listed aesthetics and CMO company behind the Elravie/Revolax hyaluronic-acid fillers and Leedstox botulinum toxin.
Founded and listed on KOSPI in 2012 upon spin-off from the former Kolmar Korea, KOLMAR KOREA runs cosmetics ODM, prescription drugs, and packaging.
KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.
Tego Science makes cell therapies Holoderm and Rosmir, and sells the 3D skin model Neoderm for CDMO and animal-alternative testing.
Wonbiogen Co.,Ltd., established September 2018, listed on KOSDAQ in December 2018, manufactures wound dressings and moist wound dressings.
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition